Navigation Links
Hospira Receives Health Canada Regulatory Approval for Symbiq™ Infusion System Software Upgrade
Date:5/20/2011

LAKE FOREST, Ill., May 20, 2011 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), a leading provider of clinical information and medication delivery technologies, today announced that the company has received regulatory approval from Health Canada for its software upgrade to the Symbiq™ infusion system. As a result, Hospira has resumed shipments of Symbiq pumps in Canada and is working with current customers in the region to upgrade to the new version of the software.

"With the upgraded Symbiq infusion system, our goal is to provide hospitals with one of the most advanced and highest quality infusion pumps available today," said Gerry Stefanatos, vice president, Canada and Latin America, Hospira. "This regulatory approval is a testament to the work we've done to help ensure the robustness, dependability and flexibility of the Symbiq device. We are now focused on partnering with hospital customers in Canada who are ready to have their current Symbiq system upgraded and new infusion pumps implemented."

The upgraded Symbiq software includes modifications to further ensure the reliability of the device. During the Symbiq modification process, Hospira:

  • enhanced the operational performance of the infusion pump to reflect customer feedback and address recent device field corrections,  
  • improved the device software to perform consistently across varying infusion pump clinical practices, and  
  • reevaluated the software design to ensure optimal operation within the product specifications.

The Symbiq infusion system is a technologically advanced infusion pump with several clinician-friendly features incorporated to help improve workflow and decrease medication errors. For example, the Symbiq LCD touch screen -- the largest infusion pump screen available -- includes intuitive layouts and touch-activated buttons. This unique touch screen technology also enables hospitals to add future applications to extend the useful life of the pump.

With Hospira MedNet™ safety software built into the device, Symbiq was the first general infusion system designed to provide additional medication-error protection by requiring users to select a drug library entry from the safety software for all drug delivery programs. Due to its highly sophisticated technology, Symbiq is one of the first devices to achieve I.V. clinical integration of infusion pumps with electronic health record systems, which can help decrease the number of steps and time required to program the infusion pump.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at http://www.hospira.com.

Private Securities Litigation Reform Act of 1995 --

A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the upgraded Symbiq infusion system. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, regulatory, legal, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K and subsequent Form 10-Q filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira to Present at the Sanford C. Bernstein Twenty-Seventh Annual Strategic Decisions Conference 2011
2. Hospira Highlights Progress in 2010 at Its 2011 Annual Meeting of Shareholders
3. Hospira Reports First-Quarter 2011 Results
4. Hospira Board Authorizes $1 Billion Share Repurchase Program
5. Hospira to Present at Bank of America / Merrill Lynch 2011 Health Care Conference May 11, 2011
6. Hospira Reinforces Importance of Clinical Surveillance Technology in Line With World Health Day Focus on Antimicrobial Resistance
7. Hospira to Host Conference Call for First-Quarter 2011 Results
8. Hospira Submits 510(k) Application to FDA for Symbiq™ Infusion System Modifications
9. Hospira Launches Enhanced TheraDoc™ Clinical Surveillance System to Support Patient Safety and Help Improve Care
10. Hologic, Hospira, Boston Scientific, Allergan to Participate in Leading Medical Device Manufacturing Symposium
11. Hospira Announces U.S. Approval of Generic Docetaxel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
Breaking Medicine News(10 mins):